

Effects of Previous Infection and Vaccination on Sympt

New England Journal of Medicine

387, 21-34

DOI: [10.1056/nejmoa2203965](https://doi.org/10.1056/nejmoa2203965)

Citation Report

#	ARTICLE	IF	CITATIONS
6	Dawn of the hybrid immunity era in long-term care facilities. <i>The Lancet Healthy Longevity</i> , 2022, 3, e451-e452.	2.0	0
7	One coronavirus infection wards off another " but only if it's a similar variant. <i>Nature</i> , 0, , .	13.7	5
11	Clinical characteristics of the Omicron variant - results from a Nationwide Symptoms Survey in the Faroe Islands. <i>International Journal of Infectious Diseases</i> , 2022, 122, 636-643.	1.5	22
13	Dengue and COVID-19: two sides of the same coin. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	16
14	Differences in Immunological Evasion of the Delta (B.1.617.2) and Omicron (B.1.1.529) SARS-CoV-2 Variants: A Retrospective Study on the Veneto Region's Population. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8179.	1.2	6
17	Immune responses to SARS-CoV-2 in dialysis and kidney transplantation. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1816-1828.	1.4	9
23	Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants. <i>Journal of Virology</i> , 2022, 96, .	1.5	12
24	A Critique of EU Digital COVID-19 Certificates: Do Vaccine Passports Endanger Privacy?. , 2022, , .		2
27	Severe pulmonary hemorrhage in a 3-week-old neonate with COVID-19 infection: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	0
29	Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. <i>Nature Communications</i> , 2022, 13, .	5.8	49
31	Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly vaccinated Asian setting: a test-negative design study. <i>Clinical Microbiology and Infection</i> , 2023, 29, 101-106.	2.8	16
33	Balancing the medical and social needs of children during the COVID-19 pandemic. <i>Medical Journal of Australia</i> , 0, , .	0.8	2
34	SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	72
35	SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. <i>Immunity</i> , 2022, 55, 1764-1778.	6.6	63
36	Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	16
37	Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar. <i>International Journal of Infectious Diseases</i> , 2022, 124, 96-103.	1.5	15
38	The importance of booster vaccination in the context of Omicron wave. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
39	Act Early and at the Right Location: SARS-CoV-2 T Cell Kinetics and Tissue Localization. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10679.	1.8	5

#	ARTICLE	IF	CITATIONS
40	Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022. <i>Emerging Infectious Diseases</i> , 2022, 28, 2119-2121.	2.0	6
41	Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection. <i>Journal of Clinical Virology</i> , 2022, 156, 105273.	1.6	19
44	Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa. <i>EClinicalMedicine</i> , 2022, 53, 101655.	3.2	21
45	Mind over what matters: How training in emotional self-regulation can strengthen the immune response in lonely elders. <i>Brain, Behavior, and Immunity</i> , 2022, 106, 231-232.	2.0	0
46	Effectiveness of BNT162b2 and CoronaVac COVID-19 Vaccination Against Asymptomatic and Symptomatic Infection of SARS-CoV-2 Omicron BA.2 in Hong Kong. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
47	Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
48	Plaque-Neutralizing Antibody to BA.2.12.1, BA.4 and BA.5 in Individuals with Three Doses of Biontech or Coronavac Vaccines, Natural Infection and Breakthrough Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
49	Trends in Confirmed COVID-19 Cases in the Korean Military Before and After the Emergence of the Omicron Variant. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	2
50	SARS-CoV-2 Vaccination in Solid-Organ Transplant Recipients. <i>Vaccines</i> , 2022, 10, 1430.	2.1	6
53	Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers. <i>Vaccine</i> , 2022, 40, 7195-7200.	1.7	17
54	Covid-19 Vaccines â€” Immunity, Variants, Boosters. <i>New England Journal of Medicine</i> , 2022, 387, 1011-1020.	13.9	266
55	COVID-19 and isolation: Risks and implications in the scenario of new variants. <i>Brazilian Journal of Infectious Diseases</i> , 2022, 26, 102703.	0.3	2
57	A Proposal to Refer to Four Coronaviruses of Limited Human Virulence â€œCommon Cold Coronavirusesâ€. <i>Journal of Infectious Diseases</i> , 2022, 226, 2047-2049.	1.9	5
58	Duration of immune protection of SARS-CoV-2 natural infection against reinfection. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	54
60	<scp>COVID</scp>â€”19: Vaccineâ€”induced immune thrombotic thrombocytopenia. <i>European Journal of Haematology</i> , 2022, 109, 619-632.	1.1	3
62	On the Origins of Omicronâ€™s Unique Spike Gene Insertion. <i>Vaccines</i> , 2022, 10, 1509.	2.1	10
64	Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 45-55.	4.6	55
65	Hybrid immunity and strategies for COVID-19 vaccination. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 2-3.	4.6	21

#	ARTICLE	IF	CITATIONS
66	Immune Evasion of SARS-CoV-2 Omicron Subvariants. <i>Vaccines</i> , 2022, 10, 1545.	2.1	19
67	SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis. <i>Gut</i> , 2023, 72, 1995-1996.	6.1	2
69	Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants. <i>Vaccines</i> , 2022, 10, 1596.	2.1	1
70	Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses. <i>Cell</i> , 2022, 185, 4333-4346.e14.	13.5	32
71	SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in northeastern Brazil. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010337.	1.3	9
73	Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. <i>Lancet Respiratory Medicine</i> , 2023, 11, 176-187.	5.2	17
74	Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	19
75	BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age. <i>Cell Reports</i> , 2022, 41, 111544.	2.9	17
76	Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. <i>Med</i> , 2022, 3, 838-847.e3.	2.2	26
77	Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. <i>New England Journal of Medicine</i> , 2022, 387, 1620-1622.	13.9	89
78	SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask. <i>Yonsei Medical Journal</i> , 2022, 63, 977.	0.9	7
79	How will previous infection or current vaccination strategies protect us from future SARS-CoV-2 variant infections?. , 2022, 1, .		0
80	Protection against Omicron from Vaccination and Previous Infection in a Prison System. <i>New England Journal of Medicine</i> , 2022, 387, 1770-1782.	13.9	40
82	Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-c2a trial. <i>Lancet Infectious Diseases</i> , 2023, 23, 295-306.	4.6	14
84	A Scoping Review of Three Dimensions for Long-Term COVID-19 Vaccination Models: Hybrid Immunity, Individual Drivers of Vaccinal Choice, and Human Errors. <i>Vaccines</i> , 2022, 10, 1716.	2.1	1
85	Original antigen sin and COVID-19: implications for seasonal vaccination. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1353-1358.	1.4	5
86	Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine. <i>Gastroenterology</i> , 2023, 164, 300-303.e3.	0.6	6
87	Covid-19 Vaccine Protection among Children and Adolescents in Qatar. <i>New England Journal of Medicine</i> , 2022, 387, 1865-1876.	13.9	37

#	ARTICLE	IF	CITATIONS
89	Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2. <i>New England Journal of Medicine</i> , 2022, 387, 1716-1718.	13.9	50
91	COVID-19 convalescent plasma therapy through the lens of the third year of the pandemic. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	1
93	Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients. <i>Vaccines</i> , 2022, 10, 1904.	2.1	6
94	Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e944-e955.	3.4	34
95	Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. <i>Nature</i> , 2023, 613, 558-564.	13.7	159
96	Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerlandâ€”A multicentre cohort study. <i>PLoS Medicine</i> , 2022, 19, e1004125.	3.9	11
97	Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection. <i>Viruses</i> , 2022, 14, 2458.	1.5	8
98	Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study. <i>Lancet Rheumatology</i> , The, 2023, 5, e36-e46.	2.2	10
100	Prevalence of SARS-CoV-2 antibodies after the Omicron surge, Kingston, Jamaica, 2022. <i>Journal of Clinical Virology Plus</i> , 2022, 2, 100124.	0.4	3
101	An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay. <i>Vaccine</i> , 2023, 41, 109-118.	1.7	17
102	Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination. <i>Journal of Infectious Diseases</i> , 2023, 227, 651-662.	1.9	7
103	Effect of the incremental protection of previous infection against Omicron infection among individuals with a hybrid of infection- and vaccine-induced immunity: a population-based cohort study in Canada. <i>International Journal of Infectious Diseases</i> , 2023, 127, 69-76.	1.5	3
104	SARS-CoV-2 Breakthrough Infection after mRNA-1273 Booster among CoronaVac-Vaccinated Healthcare Workers. <i>Infection and Chemotherapy</i> , 2022, 54, 774.	1.0	3
105	The Omicron-transformer: Rise of the subvariants in the age of vaccines. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 712-729.	0.2	9
107	Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infectionâ€”Final Update of a Living, Rapid Review. <i>Annals of Internal Medicine</i> , 2023, 176, 85-91.	2.0	6
108	Considerations of hybrid immunity and the future of adolescent COVID-19 vaccination. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 382-383.	4.6	1
111	Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. <i>PLoS Medicine</i> , 2022, 19, e1004037.	3.9	28
112	Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021â€”March, 2022: a national, observational, test-negative, case-control study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 435-444.	4.6	47

#	ARTICLE	IF	CITATIONS
113	Side-Effects following Oxford/AstraZeneca COVID-19 Vaccine in Tororo District, Eastern Uganda: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 15303.	1.2	3
114	Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. <i>Nature Communications</i> , 2022, 13, .	5.8	5
115	COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities. <i>Journal of Medical Ethics</i> , 2024, 50, 126-138.	1.0	16
116	Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity. <i>Vaccine</i> , 2023, 41, 892-902.	1.7	3
118	Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative caseâ€”control analysis. <i>PLoS Medicine</i> , 2022, 19, e1004136.	3.9	7
119	The Epidemiology of Long Coronavirus Disease in US Adults. <i>Clinical Infectious Diseases</i> , 2023, 76, 1636-1645.	2.9	37
120	Analysis of 394 COVID-19 cases infected with Omicron variant in Shenzhen: impact of underlying diseases to patientâ€™s symptoms. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	0
121	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. <i>Nature Communications</i> , 2022, 13, .	5.8	17
122	B-Cell Responses to Sars-Cov-2 mRNA Vaccines. <i>Pathogens and Immunity</i> , 2022, 7, 93-119.	1.4	0
124	Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 421-434.	4.6	24
126	Immunogenicity against the Omicron Variant after mRNA-Based COVID-19 Booster Vaccination in Medical Students Who Received Two Primary Doses of the mRNA-1273 Vaccine. <i>Vaccines</i> , 2022, 10, 2102.	2.1	1
130	Risk of Infection and Duration of Protection after the Booster Dose of the Anti-SARS-CoV-2 Vaccine BNT162b2 among Healthcare Workers in a Large Teaching Hospital in Italy: Results of an Observational Study. <i>Vaccines</i> , 2023, 11, 25.	2.1	3
131	Current evidence of COVID-19 vaccination-related cardiovascular events. <i>Postgraduate Medicine</i> , 2023, 135, 102-120.	0.9	5
133	Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada. <i>Cmaj</i> , 2022, 194, E1599-E1609.	0.9	25
134	Hybrid immunity and protection against infection during the Omicron wave in Malta. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	2
135	Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals. <i>Vaccine</i> , 2023, 41, 879-882.	1.7	2
136	Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. <i>Journal of Infection and Public Health</i> , 2023, 16, 250-256.	1.9	10
137	Time from last immunity event against infection during Omicron-dominant period in Malaysia. <i>International Journal of Infectious Diseases</i> , 2023, 128, 98-101.	1.5	3

#	ARTICLE	IF	CITATIONS
138	Impact of SARS-CoV-2 exposure history on the T _H cell and IgG response. <i>Cell Reports Medicine</i> , 2023, 4, 100898.	3.3	13
139	Towards the light at the end of the tunnel: Changes in clinical settings and political measures regarding COVID-19 from 2021, and future perspectives in Japan. <i>Global Health & Medicine</i> , 2022, 4, 327-331.	0.6	8
140	Effectiveness of COVID-19 Vaccines over 13 Months Covering the Period of the Emergence of the Omicron Variant in the Swedish Population. <i>Vaccines</i> , 2022, 10, 2074.	2.1	3
142	COVID-19 patients' clinical profile and outcome with respect to their vaccination status: A prospective observational multicentre cohort study during third wave in Western India. <i>Indian Journal of Medical Microbiology</i> , 2023, 41, 28-32.	0.3	2
143	Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. <i>Nature Communications</i> , 2023, 14, .	5.8	54
144	Prevalent and immunodominant CD8 T _H cell epitopes are conserved in SARS-CoV-2 variants. <i>Cell Reports</i> , 2023, 42, 111995.	2.9	12
145	Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. <i>Nature Medicine</i> , 2023, 29, 358-365.	15.2	108
147	Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa. <i>Nature Communications</i> , 2023, 14, .	5.8	15
148	Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2023, 12, 367-387.	1.8	22
150	Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naïve population. <i>Nature Medicine</i> , 2023, 29, 348-357.	15.2	74
151	Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device. <i>International Journal of Infectious Diseases</i> , 2023, 128, 112-120.	1.5	6
152	Omicron. , 2023, , 367-413.		0
153	Management of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Onboard a U.S. Navy Hospital Ship Amid a Global Omicron Surge. <i>Military Medicine</i> , 0, , .	0.4	0
154	A longitudinal study of SARS-CoV-2 antibody response in a subset of United States blood donors. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	0
155	The COVID-19 Pandemic—A Potential Role for Antivirals in Mitigating Pandemics. <i>Viruses</i> , 2023, 15, 303.	1.5	3
156	Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination. <i>Vaccines</i> , 2023, 11, 242.	2.1	4
158	A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529). <i>Vaccines</i> , 2023, 11, 224.	2.1	21
159	Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination—Evidence Synthesis and Implications for New COVID-19 Vaccines. <i>Biomedicines</i> , 2023, 11, 370.	1.4	15

#	ARTICLE	IF	CITATIONS
162	Reply to "Patients With Inflammatory Bowel Disease on Anti-TNF Therapy and COVID-19 Vaccination" Inflammatory Bowel Diseases, 0, , .	0.9	0
163	Vaccine Effectiveness Against the SARS-CoV-2 B.1.1.529 Omicron Variant in Solid Organ and Islet Transplant Recipients in England: A National Retrospective Cohort Study. <i>Transplantation</i> , 2023, 107, 1124-1135.	0.5	5
164	Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers. <i>Vaccines</i> , 2023, 11, 283.	2.1	3
165	Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 556-567.	4.6	242
168	The emergence of new variants and sub-variants of SARS-CoV-2 and the effectiveness of vaccines. <i>Payesh</i> , 2023, 22, 105-108.	0.1	0
169	Dynamics of Antibody Responses after Asymptomatic and Mild to Moderate SARS-CoV-2 Infections: Real-World Data in a Resource-Limited Country. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 185.	0.9	0
170	Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort. <i>Vaccine</i> , 2023, 41, 2234-2242.	1.7	7
171	Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines. <i>Viruses</i> , 2023, 15, 917.	1.5	1
172	Spheromers reveal robust T _H cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8+ T _H cell responses post SARS-CoV-2 infection. <i>Immunity</i> , 2023, 56, 864-878.e4.	6.6	28
173	Factors associated with receipt of COVID-19 vaccination and SARS-CoV-2 seropositivity among healthcare workers in Albania (February 2021–June 2022): secondary analysis of a prospective cohort study. <i>Lancet Regional Health - Europe</i> , The, 2023, 27, 100584.	3.0	6
174	19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern. <i>IScience</i> , 2023, 26, 106562.	1.9	1
175	Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studies. <i>International Journal of Infectious Diseases</i> , 2023, 131, 111-114.	1.5	6
176	Long-term follow-up of patients after COVID-19: adherence to SARS-CoV-2 vaccination and immune status. <i>Profilakticheskaya Meditsina</i> , 2022, 25, 88.	0.2	2
177	Defending against SARS-CoV-2: The T cell perspective. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
178	Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. <i>Heliyon</i> , 2023, 9, e13285.	1.4	4
179	SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies. <i>European Journal of Epidemiology</i> , 2023, 38, 237-242.	2.5	7
180	Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal. <i>Emerging Infectious Diseases</i> , 2023, 29, 569-575.	2.0	5
181	Comparable humoral and cellular immunity against Omicron variant BA.4/5 of once-boosted BA.1/2 convalescents and twice-boosted COVID-19-naïve individuals. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	2

#	ARTICLE	IF	CITATIONS
182	Comparison of Two Commercially Available Interferon- γ Release Assays for T-Cell-Mediated Immunity and Evaluation of Humoral Immunity against SARS-CoV-2 in Healthcare Workers. <i>Diagnostics</i> , 2023, 13, 637.	1.3	4
183	Inflammatory Biomarkers Differ among Hospitalized Veterans Infected with Alpha, Delta, and Omicron SARS-CoV-2 Variants. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 2987.	1.2	5
184	Weighted gene co-expression network-based identification of genetic effect of mRNA vaccination and previous infection on SARS-CoV-2 infection. <i>Cellular Immunology</i> , 2023, 385, 104689.	1.4	1
185	Early vs Deferred Non-messenger RNA COVID-19 Vaccination Among Chinese Patients With a History of Inactive Uveitis. <i>JAMA Network Open</i> , 2023, 6, e2255804.	2.8	2
186	Estimating the share of SARS-CoV-2-immunologically naïve individuals in Germany up to June 2022. <i>Epidemiology and Infection</i> , 2023, 151, .	1.0	4
187	Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. <i>Med</i> , 2023, 4, 191-215.e9.	2.2	16
188	Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. <i>Lancet</i> , The, 2023, 401, 833-842.	6.3	151
190	Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-associated Encounters in Adults During Delta and Omicron Predominance. <i>Journal of Infectious Diseases</i> , 2023, 227, 1348-1363.	1.9	4
191	Effectiveness of mRNA vaccine against Omicron-related infections in the real world: A systematic review and meta-analysis. <i>American Journal of Infection Control</i> , 2023, 51, 1049-1055.	1.1	4
192	Evaluation of the Abbott Panbio [®] COVID-19 antigen detection rapid diagnostic test among healthcare workers in elderly care. <i>PLoS ONE</i> , 2023, 18, e0276244.	1.1	3
194	Lung tropism in hospitalized patients following infection with SARS-CoV-2 variants from D614G to Omicron BA.2. <i>Communications Medicine</i> , 2023, 3, .	1.9	5
195	Prevention of COVID-19 during youth ice hockey. <i>Applied Physiology, Nutrition and Metabolism</i> , 0, , .	0.9	0
196	SARS-CoV-2 in animals: susceptibility of animal species, risk for animal and public health, monitoring, prevention and control. <i>EFSA Journal</i> , 2023, 21, .	0.9	16
197	Value of Laboratory Indicators in Predicting Pneumonia in Symptomatic COVID-19 Patients Infected with the SARS-CoV-2 Omicron Variant. <i>Infection and Drug Resistance</i> , 0, Volume 16, 1159-1170.	1.1	4
198	SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. <i>Bone Marrow Transplantation</i> , 2023, 58, 567-580.	1.3	12
199	Development and validation of a prognostic model based on immune variables to early predict severe cases of SARS-CoV-2 Omicron variant infection. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
200	Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). <i>Expert Review of Vaccines</i> , 2023, 22, 288-298.	2.0	4
202	Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 816-827.	4.6	35

#	ARTICLE	IF	CITATIONS
203	Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study. <i>Lancet Infectious Diseases, The</i> , 2023, 23, 799-805.	4.6	31
204	Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case-case study based on electronic health records. <i>Influenza and Other Respiratory Viruses</i> , 2023, 17, .	1.5	0
209	Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study. <i>Lancet Microbe, The</i> , 2023, 4, e309-e318.	3.4	26
210	Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization. <i>IScience</i> , 2023, 26, 106457.	1.9	3
211	Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2. <i>Journal of Immunology</i> , 2023, 210, 1236-1246.	0.4	4
212	Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome. <i>Nature Communications</i> , 2023, 14, .	5.8	17
213	Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study. <i>Infection</i> , 2023, 51, 1093-1102.	2.3	3
214	Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers. <i>Nature Communications</i> , 2023, 14, .	5.8	8
215	COVID-19 patient and personal safety - lessons learnt for pandemic preparedness and the way to the next normal. <i>Antimicrobial Resistance and Infection Control</i> , 2023, 12, .	1.5	0
216	Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	7
217	Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic. <i>International Journal of Infectious Diseases</i> , 2023, 132, 72-79.	1.5	4
218	Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation. <i>Lancet Microbe, The</i> , 2023, 4, e495-e505.	3.4	3
219	SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. <i>Vaccines</i> , 2023, 11, 849.	2.1	12
220	Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	11
221	SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	4
222	Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis. <i>The Lancet Child and Adolescent Health</i> , 2023, 7, 379-391.	2.7	19
323	Epidemiology of the COVID-19 Pandemic: An Update. , 2024, , 411-426.		0
329	Clinical course and management of COVID-19 in the era of widespread population immunity. <i>Nature Reviews Microbiology</i> , 2024, 22, 75-88.	13.6	1

#	ARTICLE	IF	CITATIONS
336	Silent battles: immune responses in asymptomatic SARS-CoV-2 infection. , 2024, 21, 159-170.		3
357	SARS-CoV-2, COVID-19, and Children: Myths and Evidence. , 2023, , 503-520.		0